1. Scrip
  2. >>R&D

Buoyed By Phase III Rosacea Success, Foamix Plans Commercial Transition

 
• By Emily Hayes

Market of dermatologists prescribing for rosacea and acne is very focused, so Foamix says it can manage commercialization of topical minocycline foam on its own.  

wooden ladder shot from below. getting up in the sky as a symbol of career and increase

Foamix Pharmaceuticals Ltd. is readying to make the leap from clinical-stage to a commercial entity with two wholly owned topical minocycline foam products – one for rosacea and one for acne.

Based in Bridgewater, NJ, Foamix is developing a pipeline of topical therapies for unmet needs in dermatology. It says its two lead products – FMX101 and FMX103 – will be the first topical formulations of the oral, systemic antibiotic minocycline

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.